FITCH reaffirmed Germany's AAA sovereign credit rating and kept the outlook at stable.

AstraZeneca China said 13 of its innovative medicines were included in the new version of China’s National Reimbursement Drug List (NRDL) and the commercial insurance innovative drug list, expanding reimbursement and access for oncology, respiratory, immune, renal and rare-disease patients. On the NRDL, two medicines were listed for the first time, five gained new indications, four were renewed and one was reclassified into regular Category B. Separately, one AstraZeneca medicine was newly included in the commercial insurance innovative drug list.

诺和诺德(NVO.N)：减重药物Frehemgo已获沙特阿拉伯批准，目前正接受美国食品药品监督管理局（FDA）及其他监管机构的审查。